vs
Ameris Bancorp（ABCB）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
Ameris Bancorp的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$314.4M vs $199.9M），Ameris Bancorp净利率更高（35.1% vs -29.5%，领先64.6%），Ameris Bancorp同比增速更快（10.0% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 2.3%）
Ameris Bancorp是总部位于美国佐治亚州亚特兰大的银行控股企业，旗下子公司Ameris Bank在佐治亚、阿拉巴马、佛罗里达、北卡罗来纳、南卡罗来纳五州运营全服务网点，另在多州设有抵押贷款专属站点，同时面向个人及企业客户提供便捷的线上及移动银行服务。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
ABCB vs APLS — 直观对比
营收规模更大
ABCB
是对方的1.6倍
$199.9M
营收增速更快
ABCB
高出15.9%
-5.9%
净利率更高
ABCB
高出64.6%
-29.5%
两年增速更快
APLS
近两年复合增速
2.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $314.4M | $199.9M |
| 净利润 | $110.5M | $-59.0M |
| 毛利率 | — | — |
| 营业利润率 | — | -25.6% |
| 净利率 | 35.1% | -29.5% |
| 营收同比 | 10.0% | -5.9% |
| 净利润同比 | 2.0% | -62.2% |
| 每股收益（稀释后） | $1.63 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABCBAPLS
| Q1 26 | $314.4M | — | ||
| Q4 25 | $307.1M | $199.9M | ||
| Q3 25 | $314.2M | $458.6M | ||
| Q2 25 | $300.7M | $178.5M | ||
| Q1 25 | $285.9M | $166.8M | ||
| Q4 24 | $290.8M | $212.5M | ||
| Q3 24 | $283.8M | $196.8M | ||
| Q2 24 | $300.6M | $199.7M |
净利润ABCBAPLS
| Q1 26 | $110.5M | — | ||
| Q4 25 | $108.4M | $-59.0M | ||
| Q3 25 | $106.0M | $215.7M | ||
| Q2 25 | $109.8M | $-42.2M | ||
| Q1 25 | $87.9M | $-92.2M | ||
| Q4 24 | $94.4M | $-36.4M | ||
| Q3 24 | $99.2M | $-57.4M | ||
| Q2 24 | $90.8M | $-37.7M |
营业利润率ABCBAPLS
| Q1 26 | — | — | ||
| Q4 25 | 45.9% | -25.6% | ||
| Q3 25 | 43.6% | 48.7% | ||
| Q2 25 | 47.4% | -18.6% | ||
| Q1 25 | 39.5% | -50.0% | ||
| Q4 24 | 43.3% | -12.3% | ||
| Q3 24 | 44.4% | -24.0% | ||
| Q2 24 | 42.1% | -14.7% |
净利率ABCBAPLS
| Q1 26 | 35.1% | — | ||
| Q4 25 | 44.2% | -29.5% | ||
| Q3 25 | 33.7% | 47.0% | ||
| Q2 25 | 36.5% | -23.6% | ||
| Q1 25 | 30.8% | -55.3% | ||
| Q4 24 | 42.5% | -17.1% | ||
| Q3 24 | 35.0% | -29.2% | ||
| Q2 24 | 30.2% | -18.9% |
每股收益（稀释后）ABCBAPLS
| Q1 26 | $1.63 | — | ||
| Q4 25 | $1.59 | $-0.40 | ||
| Q3 25 | $1.54 | $1.67 | ||
| Q2 25 | $1.60 | $-0.33 | ||
| Q1 25 | $1.27 | $-0.74 | ||
| Q4 24 | $1.35 | $-0.30 | ||
| Q3 24 | $1.44 | $-0.46 | ||
| Q2 24 | $1.32 | $-0.30 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $466.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.1B | $370.1M |
| 总资产 | $28.1B | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABCBAPLS
| Q1 26 | — | — | ||
| Q4 25 | — | $466.2M | ||
| Q3 25 | — | $479.2M | ||
| Q2 25 | — | $370.0M | ||
| Q1 25 | — | $358.4M | ||
| Q4 24 | — | $411.3M | ||
| Q3 24 | — | $396.9M | ||
| Q2 24 | — | $360.1M |
股东权益ABCBAPLS
| Q1 26 | $4.1B | — | ||
| Q4 25 | $4.1B | $370.1M | ||
| Q3 25 | $4.0B | $401.2M | ||
| Q2 25 | $3.9B | $156.3M | ||
| Q1 25 | $3.8B | $164.2M | ||
| Q4 24 | $3.8B | $228.5M | ||
| Q3 24 | $3.7B | $237.1M | ||
| Q2 24 | $3.6B | $264.3M |
总资产ABCBAPLS
| Q1 26 | $28.1B | — | ||
| Q4 25 | $27.5B | $1.1B | ||
| Q3 25 | $27.1B | $1.1B | ||
| Q2 25 | $26.7B | $821.4M | ||
| Q1 25 | $26.5B | $807.3M | ||
| Q4 24 | $26.3B | $885.1M | ||
| Q3 24 | $26.4B | $901.9M | ||
| Q2 24 | $26.5B | $904.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-14.3M |
| 自由现金流率自由现金流/营收 | — | -7.1% |
| 资本支出强度资本支出/营收 | — | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $45.0M |
8季度趋势，按日历期对齐
经营现金流ABCBAPLS
| Q1 26 | — | — | ||
| Q4 25 | $390.2M | $-14.2M | ||
| Q3 25 | $104.9M | $108.5M | ||
| Q2 25 | $61.4M | $4.4M | ||
| Q1 25 | $116.9M | $-53.4M | ||
| Q4 24 | $154.2M | $19.4M | ||
| Q3 24 | $102.2M | $34.1M | ||
| Q2 24 | $-97.1M | $-8.3M |
自由现金流ABCBAPLS
| Q1 26 | — | — | ||
| Q4 25 | $369.6M | $-14.3M | ||
| Q3 25 | $100.5M | $108.3M | ||
| Q2 25 | $53.7M | $4.4M | ||
| Q1 25 | $114.2M | $-53.4M | ||
| Q4 24 | $140.7M | $19.3M | ||
| Q3 24 | $99.8M | — | ||
| Q2 24 | $-100.3M | $-8.4M |
自由现金流率ABCBAPLS
| Q1 26 | — | — | ||
| Q4 25 | 120.4% | -7.1% | ||
| Q3 25 | 32.0% | 23.6% | ||
| Q2 25 | 17.9% | 2.5% | ||
| Q1 25 | 39.9% | -32.0% | ||
| Q4 24 | 48.4% | 9.1% | ||
| Q3 24 | 35.2% | — | ||
| Q2 24 | -33.4% | -4.2% |
资本支出强度ABCBAPLS
| Q1 26 | — | — | ||
| Q4 25 | 6.7% | 0.1% | ||
| Q3 25 | 1.4% | 0.0% | ||
| Q2 25 | 2.5% | 0.0% | ||
| Q1 25 | 0.9% | 0.0% | ||
| Q4 24 | 4.6% | 0.0% | ||
| Q3 24 | 0.8% | 0.0% | ||
| Q2 24 | 1.1% | 0.0% |
现金转化率ABCBAPLS
| Q1 26 | — | — | ||
| Q4 25 | 3.60× | — | ||
| Q3 25 | 0.99× | 0.50× | ||
| Q2 25 | 0.56× | — | ||
| Q1 25 | 1.33× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | -1.07× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABCB
暂无分部数据
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
